Fig. 6

Immunotherapy-treated glioma datasets. A Stacked bar plots representing relative proportion of 10 broader category of immune cell types from LM10 across samples treated with checkpoint inhibitor. B Stacked bar plots representing the relative proportions of 4 malignant cell-states across all immunotherapy treated samples. C Forest plot representing the association between their dichotomous immune cell fractions and their overall survival. D Monocyte-based gene expression clusters represented by tSNE followed by E Kaplan–Meier curves denoting distinct survival between the two clusters. F Boxplots depicting differential distribution of epithelial-mesenchymal transition markers between the two immune-based survival groups derived from monocytes from samples treated with checkpoint inhibitor. G Scatter plots representing significant positive correlations between the epithelial-mesenchymal transition and the T cell exhaustion scores both in patients treated with a checkpoint inhibitor, as well as larger cohorts. H Forest plot representing the insignificant or inconsistent association between their dichotomous monocytic fractions in non-immunotherapy or non-checkpoint inhibitor treated IDH-WT tumors (from TCGA, CGGA325 and CGGA693) and their overall survival